Clinical trial for Advanced Cancer
Official title A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
ClinicalTrials.gov ID: NCT04657068
What this study is testing
What is ART0380?
ART0380 is an investigational medicine, taken by mouth once daily, being studied as a potential treatment for advanced cancer.
Plain-language explanation of the investigational treatment. It is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The study aims to find a safe dose of ART0380, learn its side effects, and see how well it works alone or with chemotherapy drugs gemcitabine or irinotecan.
- Who it's for
- Adults who have advanced or metastatic solid cancers such as ovarian, colorectal, pancreatic, endometrial, or related cancers.
- What's involved
- Participants will receive ART0380, sometimes together with gemcitabine or irinotecan, and will undergo regular medical visits and tests to monitor safety and effect.
- Phase 2: a mid-size study of how well it works
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- General
- Signed informed consent
- Discontinued all previous treatments for cancer for at least 21 days or 5 half-lives, whichever is shorter, and recovered from the acute effects of...
- If patients have a known germline BRCA mutation or a cancer with a somatic BRCA mutations or which is HRD positive and for which there is an approved...
- At least 1 radiologically evaluable lesion (measurable and/or non-measurable) that can be assessed at baseline and is suitable for repeated...
You likely can't join if
- Women who are pregnant, breast feeding, or who plan to become pregnant while in the study or within 7 months after the last administration of study...
- Men who plan to father a child while in the study or within5 months after the last administration of study treatment
- Serious concomitant systemic disorder that would compromise the participants ability to adhere to the protocol including: one or more opportunistic...
- Have ongoing interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic).
- Moderate or severe cardiovascular disease
- Valvulopathy that is severe, moderate, or deemed clinically significant
See the full eligibility criteria
Who can join
- General
- Signed informed consent
- Discontinued all previous treatments for cancer for at least 21 days or 5 half-lives, whichever is shorter, and recovered from the acute effects of therapy to CTCAE Grade ≤1.
- If patients have a known germline BRCA mutation or a cancer with a somatic BRCA mutations or which is HRD positive and for which there is an approved PARP inhibitor, participants should have received such treatment...
- At least 1 radiologically evaluable lesion (measurable and/or non-measurable) that can be assessed at baseline and is suitable for repeated radiological evaluation by RECIST v1.1 or Prostate Cancer Working Group-3...
- Acceptable hematologic, renal, hepatic, and coagulation functions independent of transfusions and granulocyte colony-stimulating factor
- Non-irradiated tumor tissue sample (archival or newly obtained core biopsy of a tumor lesion) available for submission for analysis.
- Female patients of childbearing potential and male patients with female partners of childbearing potential are required to use highly effective contraception plus one barrier method during their participation in the...
- Estimated life expectancy of ≥12 weeks
- Reliable and willing to make themselves available for the duration of the study and are willing to follow study procedures
- Advanced or metastatic cancer which is refractory to standard therapies, or for which no standard therapies exist, or for which the investigator feels no other active therapy is required for the duration of the study
- Advanced or metastatic cancer for which irinotecan is an appropriate treatment. Prior treatment with irinotecan is permitted.
- Patients with advanced or metastatic solid tumors with alterations to the ATM gene likely to predict for loss of ATM protein
- Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1
- For France only ART0380 Monotherapy; Patient that is not eligible for curative treatment, for whom all standard of care therapies have failed and no therapies known to provide clinical benefit are available.
- Combination arms; Patients for which irinotecan is an appropriate treatment. Prior treatment with irinotecan is permitted.
- Patients with a known germline BRCA mutation, or a cancer with a known somatic BRCA mutation, or which is known to be HRD positive, and for which there is an approved PARP inhibitor should have received such treatment...
- Females with histologically-confirmed diagnosis of high grade serous carcinoma of the ovary, fallopian tube or primary peritoneum that is not amenable to curative therapy
- Platinum-resistant disease. Patients must not have had primary platinum-refractory disease (disease that progressed during first-line platinum-based therapy).
- No more than one prior regimen in the platinum-resistant setting. Hormonal therapies and antiangiogenic therapies (as single agents) and PARP inhibitors used as maintenance therapy are not considered as separate lines...
- Have not received prior treatment with gemcitabine unless administered in combination with a platinum with no disease progression within 12 months after completion of that regimen
- Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1 specific to Part B3
- Patients should have received taxane/platinum chemotherapy, unless contraindicated.
- Measurable disease. specific to Part B4
- Advanced or metastatic solid cancers of any histology with biological selection
- If a PD-1/PDL-1 inhibitor (eg, pembrolizumab) is approved and available for the patient's cancer, the patient should have received such treatment before participating in this study.
- Radiologically evaluable disease
- Performance status of 0-1 on the ECOG scale specific to Part B5
- Metastatic CRC with alterations to the ATM gene
- Participants should have previously received appropriate prior lines of therapy in this setting.
- Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1.
- Patients have received a maximum of 2 prior chemotherapy regimens for the treatment of CRC.
- Serum albumin ≥3g/dL within 7 days prior to first dose.
- ECOG Performance Status must be stable for at least 2 weeks prior to enrollment.
- Metastatic or locally advanced PDAC or acinar cell carcinoma with alterations to the ATM gene
- Participants must have received at least 1 prior chemotherapy regimen for the treatment of the advanced disease OR have received neoadjuvant/adjuvant therapy with recurring occurring \<6 months following completion of...
- Have at least 1 measurable lesion assessable using standard techniques by RECIST v1.1. Previously irradiated lesions may not be considered target lesions.
- Serum albumin ≥3g/dL within 7 days prior to first dose.
- ECOG Performance Status must be stable for at least 2 weeks prior to enrollment.
- Must have the clinical capacity to complete at least one 21-day treatment cycle without, in the investigator's judgment, a foreseeable need for prolonged hospitalization related to their underlying disease. General
What rules you out
- Women who are pregnant, breast feeding, or who plan to become pregnant while in the study or within 7 months after the last administration of study treatment
- Men who plan to father a child while in the study or within5 months after the last administration of study treatment
- Serious concomitant systemic disorder that would compromise the participants ability to adhere to the protocol including: one or more opportunistic HIV/AIDs-related infections within the past 12 months, a known...
- Have ongoing interstitial lung disease or pneumonitis (whether symptomatic or asymptomatic).
- Moderate or severe cardiovascular disease
- Valvulopathy that is severe, moderate, or deemed clinically significant
- Documented major electrocardiogram (ECG) abnormalities which are clinically significant
- Symptomatic or uncontrolled brain metastases, spinal cord compression, or leptomeningeal disease requiring concurrent treatment
- Received a live vaccine within 30 days before the first dose of study treatment
- History or current evidence of any condition, therapy, or laboratory abnormality that might confound the results of the study, interfere with the patient's participation for the full duration of the study, or is not in...
- Recent major surgery within 4 weeks prior to entry into the study or minor surgery within 1 week of entry into the study
- Drainage for ascites, pleural effusion or pericardial fluid within 4 weeks before the first dose of study treatment.
- A significant bleeding disorder or vasculitis or had a Grade ≥3 bleeding episode within 12 weeks prior to enrollment
- Patients who have symptoms or signs of clinically unacceptable deterioration of the primary disease at the time of screening.
- Patients who are known to be homozygous for both UGT1A1 \ 6 and \ 28 (UGT1A1 7/7 genotype), or simultaneously heterozygous for both UGT1A1 \ 6 and \ 28.
- Patients receiving strong inhibitors of UGT1A1 within 2 weeks before the first dose of study treatment
- Part A3 Fed-fasted cohort only: Patients receiving acid reducing agents within 1 week before the first dose of study treatment will be excluded
- Part B6: Neuroendocrine (carcinoid, islet cell) or adenosquamous carcinoma pancreatic cancer
- Parts B5 and B6: Initiation of opioids in the previous 2 weeks.
- Parts B5 and B6: Weight loss \>10% in the previous 8 weeks.
- Parts B5 and B6: Active intestinal obstruction, ileus, or significant malabsorption.
The study team makes the final eligibility decision.
Where it is enrolling
- Birmingham, Alabama, United States
- Scottsdale, Arizona, United States
- Los Angeles, California, United States
- Santa Rosa, California, United States
- Denver, Colorado, United States
- Washington D.C., District of Columbia, United States
- Fort Myers, Florida, United States
- Jacksonville, Florida, United States
- Indianapolis, Indiana, United States
- Boston, Massachusetts, United States
- Maple Grove, Minnesota, United States
- Rochester, Minnesota, United States
- St Louis, Missouri, United States
- East Syracuse, New York, United States
- Lake Success, New York, United States
- New York, New York, United States
- Cincinnati, Ohio, United States
- Maumee, Ohio, United States
- Oklahoma City, Oklahoma, United States
- Portland, Oregon, United States
+ 30 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part, but confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
This study is enrolling now at Birmingham, Alabama, United States; Scottsdale, Arizona, United States; Los Angeles, California, United States; Santa Rosa, California, United States; Denver, Colorado, United States; Washington D.C., District of Columbia, United States and 44 more locations. Enter your location above to see the nearest enrolling site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool that is independent of the study sponsor. Details come from ClinicalTrials.gov. The study team decides eligibility, and your own doctor gives medical advice.